A novel curcumin derivative, C210, activates the Epstein–Barr virus (EBV) lytic cycle without producing infectious virions by disrupting HSP90. This discovery opens avenues for safer EBV-positive cancer therapies.
Shorter Oral Regimens Measure Up to Standard Ones for Rifampin-Resistant TB
In the search for shorter, effective, and safe regimens to treat fluoroquinolone-susceptible, rifampin-resistant tuberculosis (TB), three 9-month regimens incorporating newer and repurposed drugs proved on